ATE359090T1 - Monoklonale antikörper spezifisch gegen vegf- rezeptoren und ihre verwendung - Google Patents

Monoklonale antikörper spezifisch gegen vegf- rezeptoren und ihre verwendung

Info

Publication number
ATE359090T1
ATE359090T1 AT95911659T AT95911659T ATE359090T1 AT E359090 T1 ATE359090 T1 AT E359090T1 AT 95911659 T AT95911659 T AT 95911659T AT 95911659 T AT95911659 T AT 95911659T AT E359090 T1 ATE359090 T1 AT E359090T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
antibodies specific
vegf receptors
receptor
vegf
Prior art date
Application number
AT95911659T
Other languages
English (en)
Inventor
Patricia Rockwell
Neil I Goldstein
Original Assignee
Imclone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc filed Critical Imclone Systems Inc
Application granted granted Critical
Publication of ATE359090T1 publication Critical patent/ATE359090T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95911659T 1994-02-10 1995-02-10 Monoklonale antikörper spezifisch gegen vegf- rezeptoren und ihre verwendung ATE359090T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19604194A 1994-02-10 1994-02-10
US08/326,552 US5840301A (en) 1994-02-10 1994-10-20 Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors

Publications (1)

Publication Number Publication Date
ATE359090T1 true ATE359090T1 (de) 2007-05-15

Family

ID=26891612

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95911659T ATE359090T1 (de) 1994-02-10 1995-02-10 Monoklonale antikörper spezifisch gegen vegf- rezeptoren und ihre verwendung

Country Status (7)

Country Link
US (2) US5840301A (de)
EP (2) EP0741748B1 (de)
AT (1) ATE359090T1 (de)
AU (1) AU1914795A (de)
CA (1) CA2185683A1 (de)
DE (1) DE69535459T2 (de)
WO (1) WO1995021868A1 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US5367057A (en) * 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US8211422B2 (en) * 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US6872699B2 (en) 1992-11-13 2005-03-29 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften, E.V. Truncated Flk-1 receptor protein, methods of use and a recombinant vector containing a nucleotide encoding the truncated Flk-1 protein
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
AUPM379394A0 (en) * 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - i
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
IL117645A (en) * 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
ES2202469T5 (es) 1995-09-08 2011-06-06 Genentech, Inc. Proteína relacionada con el vegf.
US7034009B2 (en) 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US5942385A (en) * 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
AU2066797A (en) * 1996-03-21 1997-10-10 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
US6986890B1 (en) * 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
DE69736222T2 (de) * 1996-11-21 2007-05-24 Kyowa Hakko Kogyo K.K. Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper.
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
PT971959E (pt) * 1997-04-07 2006-05-31 Genentech Inc Anticorpos humanizados e metodos para formar anticorpos humanizados
US6852533B1 (en) * 1998-01-23 2005-02-08 Cornell Research Foundation, Inc. Purified populations of stem cells
WO1999040118A1 (en) * 1998-02-04 1999-08-12 Kyowa Hakko Kogyo Co., Ltd. Antibodies against human vegf receptor kdr
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
AU767731B2 (en) * 1998-05-20 2003-11-20 Kyowa Hakko Kirin Co., Ltd. Gene recombinant antibodies
AU2004200700B2 (en) * 1998-05-20 2006-08-31 Kyowa Hakko Kirin Co., Ltd. Gene Recombinant Antibody
US20030175271A1 (en) * 1998-05-20 2003-09-18 Kyowa Hakko Kogyo Co., Ltd. VEGF activity inhibitor
JP3679406B2 (ja) * 1998-05-20 2005-08-03 協和醗酵工業株式会社 遺伝子組換え抗体
CA2328893A1 (en) * 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Vegf activity inhibitors
EP1160572A4 (de) * 1999-03-04 2002-03-20 Kyowa Hakko Kogyo Kk Mittel zur diagnose und therapie von leukämie
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US6342219B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
CZ20014083A3 (cs) * 1999-05-14 2002-08-14 Imclone Systems Incorporated Léčivo pro indikaci růstu refrakterních nádorů
WO2000079275A1 (en) * 1999-06-17 2000-12-28 Kyowa Hakko Kogyo Co., Ltd. Diagnostics and remedies for diseases with participation of macrocytes/macrophages
US20020049247A1 (en) * 2000-01-12 2002-04-25 Chen James C. Novel treatment for eye disease
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
AU2001228742A1 (en) * 2000-02-04 2001-08-14 Supratek Pharma, Inc. Ligand for vascular endothelial growth factor receptor
WO2001058240A2 (en) * 2000-02-10 2001-08-16 Massachusetts Eye And Ear Infirmary Photodynamic therapy for treating conditions of the eye
EP1130032A1 (de) * 2000-02-28 2001-09-05 Gesellschaft für biotechnologische Forschung mbH (GBF) Einzelkette-Antikörper die den menschlichen vaskulären endothelialen Wachstumsfaktorrezeptor-2 (VEGFR-2/KDR) erkennen
AU2001243418A1 (en) * 2000-03-03 2001-09-17 Imclone Systems Incorporated Ve-cadherin and vegfr-2 antagonists for therapeutic modulation of angiogenesis
WO2001075109A2 (en) * 2000-03-31 2001-10-11 Imclone Systems Incorporated Antagonist antibodies to ve-cadherin without adverse effects on vascular permeability
CA2409991A1 (en) * 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
WO2002011677A2 (en) * 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
EP1325121A2 (de) * 2000-10-13 2003-07-09 Institut de Cardiologie de Montreal Antisense oligonukleotid gerichtet gegen gene von vegf rezeptoren von säugetieren und deren verwendungen
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
WO2002081649A2 (en) 2001-04-06 2002-10-17 The Trustees Of The University Of Pennsylvania ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
CA2445898A1 (en) 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
CA2450793A1 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20040247597A1 (en) * 2001-06-20 2004-12-09 Peter Carmeliet Method of treating atherosclerosis and other inflammatory diseases
JP2005518336A (ja) * 2001-06-26 2005-06-23 イムクローン システムズ インコーポレイティド Ｖｅｇｆ受容体に結合する二重特異性抗体
JP2005515967A (ja) * 2001-07-13 2005-06-02 イムクローン　システムズ　インコーポレイティド 乳癌を治療するためのｖｅｇｆｒ−１抗体
US20050026220A1 (en) * 2001-08-10 2005-02-03 Shahin Rafii Isolation and mobilization of stem cells expressing vegfr-1
FR2832154B1 (fr) * 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
AU2002367566B2 (en) 2001-11-20 2008-10-16 Duke University Interfacial biomaterials
CN101474404A (zh) * 2002-03-04 2009-07-08 伊姆克罗尼系统公司 用血管内皮生长因子受体拮抗剂抑制肿瘤生长的联合疗法
GB0206072D0 (en) * 2002-03-15 2002-04-24 Astrazeneca Ab Epitope
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20040229294A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US20050186204A1 (en) * 2002-06-28 2005-08-25 Peter Carmeliet Use of antibodies against FLT-1 for the treatment of osteoporosis
EP1622941A2 (de) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Methode zur produktion von anti-egfr antikörpern
US8431396B2 (en) 2003-03-21 2013-04-30 The Cleveland Clinic Foundation Anti-angiogenic peptides
WO2005001053A2 (en) 2003-06-09 2005-01-06 Samuel Waksal Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
US7402399B2 (en) * 2003-10-14 2008-07-22 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
WO2005069906A2 (en) * 2004-01-16 2005-08-04 Yale University Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases
CA2560305C (en) * 2004-03-19 2016-07-05 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
US20060234210A1 (en) * 2004-04-14 2006-10-19 Affinergy, Inc. Filtration device and method for removing selected materials from biological fluids
CN101102791B (zh) * 2004-11-18 2011-12-14 英克隆有限责任公司 抗血管内皮生长因子受体-1的抗体
EP1962903B1 (de) * 2005-12-15 2013-03-13 MedImmune Limited Kombination eines angiopoetin-2-antagonisten und eines vegf-a, kdr- und/oder fltl-antagonisten zur behandlung von krebs
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
WO2008093246A2 (en) 2007-02-02 2008-08-07 Vegenics Limited Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
KR100883430B1 (ko) * 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
CA2705152C (en) 2007-11-09 2016-10-11 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
WO2011005377A2 (en) * 2009-05-27 2011-01-13 Mount Sinai School Of Medicine Of New York University Compositions and methods comprising vegfr-2 and vegfr-3 antagonists for the treatment of metastatic disease
CA2776143A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2011106697A1 (en) 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
EP2994758B1 (de) 2013-05-08 2017-12-20 Opthea Limited Biomarker für altersbedingte makuladegeneration (amd)
WO2016158851A1 (ja) 2015-03-30 2016-10-06 日産化学工業株式会社 血管内皮増殖因子受容体に結合する核酸アプタマー
CN106892980B (zh) * 2017-01-25 2020-08-04 长春金赛药业有限责任公司 抗vegfr2单克隆抗体及其应用
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
DE69232718T2 (de) * 1991-02-22 2003-04-03 American Cyanamid Co., Madison Identifizierung eines menschlichen rezeptor-tyrosinkinasegens
US5185438A (en) * 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
US5270458A (en) * 1991-04-02 1993-12-14 The Trustees Of Princeton University Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
AU3236793A (en) * 1991-12-12 1993-07-19 Berlex Laboratories, Inc. Recombinant and chimeric antibodies to c-erbB-2
AU4025193A (en) * 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
CA2085291A1 (en) * 1992-07-30 1994-01-31 Martin L. Breitman Novel receptor tyrosine kinase
AU687727B2 (en) * 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
ATE250138T1 (de) * 1992-10-29 2003-10-15 Univ Australian Angiogenese-inhibierende antikörper
CN1701814A (zh) * 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1
AUPM379394A0 (en) * 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - i

Also Published As

Publication number Publication date
DE69535459D1 (de) 2007-05-24
CA2185683A1 (en) 1995-08-17
EP0741748A1 (de) 1996-11-13
AU1914795A (en) 1995-08-29
DE69535459T2 (de) 2007-12-13
EP1602668A1 (de) 2005-12-07
EP0741748A4 (de) 2000-07-05
EP0741748B1 (de) 2007-04-11
US5840301A (en) 1998-11-24
WO1995021868A1 (en) 1995-08-17
US5874542A (en) 1999-02-23

Similar Documents

Publication Publication Date Title
ATE359090T1 (de) Monoklonale antikörper spezifisch gegen vegf- rezeptoren und ihre verwendung
NO991162D0 (no) Monoklonale antistoffer mot det ekstracellulµre domene av humant VEGF-reseptorprotein (KDR)
DE69925730D1 (de) 4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten
DE69617896D1 (de) Humaner monoklonaler Antikörper gegen VEGF
ATE389721T1 (de) Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen
FI956112L (fi) Monoklonaalinen anti- V-integriinivasta-aine
ATE468397T1 (de) Humane trk rezeptoren und neurotrofische faktor - inhibitoren
FI964845A7 (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
DK1223964T3 (da) APRIL-receptor og anvendelser deraf
ATE361364T1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
EP1071458A4 (de) Humanisierter antikörper und dessen verwendungen
DE69509765D1 (de) N-heterocyclyl sulphonamid-derivate und ihre verwendung als endothelin-antagonisten
FI963004A7 (fi) Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
DE60015296D1 (de) Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
DE60107221D1 (de) Indolin-2-on derivate und deren verwendung als liganden der ocytocin rezeptoren
DE60106607D1 (de) Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
DE60114413D1 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
SE9604731D0 (sv) A component of intercellular junctions in the endothelium
DE69431843D1 (de) Il-8 inhibitoren
DE60038608D1 (de) Anti-idiotypische antikörper gegen antikörper, welche die bindung zwischen immunoglobulin e und seinem hochaffinitätsrezeptor hemmen
ATE260258T1 (de) Substituierte isochinoline derivate und ihre verwendung als anticonvulsiva
DE69028713D1 (de) Schimäre immunoglobuline für cd4-rezeptoren
DE69129582D1 (de) Antikörper gegen menschlichen plasmin-alpha 2-plasmininhibitor-komplex, hybridoma und immunoassay
ATE208764T1 (de) Isazole derivate als fibrinogen-rezeptor- antagonisten
DE69623941D1 (de) Phenyl derivate und ihre verwendung als endothelin rezeptor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0741748

Country of ref document: EP

REN Ceased due to non-payment of the annual fee